Clinical trial / 2013
Daily pomegranate juice intake showed no significant impact on PSA kinetics or pain scores in patients with advanced prostate cancer.
In a phase IIb trial, 98 patients with advanced prostate cancer received either 500 ml of pomegranate juice or 500 ml of placebo beverage daily for 4 weeks, followed by 250 ml of pomegranate juice daily for all patients for another 4 weeks. Adherence was high, with 94 patients (96%) completing the first period and 87 patients (89%) completing both periods. No differences were detected between the two groups regarding PSA kinetics and pain scores, and no grade 3 or higher toxicities occurred.
- Study type
- Phase IIb double-blind randomized placebo-controlled trial
- Who was studied
- 102 enrolled patients with histologically confirmed prostate cancer (PSA ≥ 5 ng/ml; 68% castration resistant)
- What was measured
- Significant difference in PSA serum levels after 1 month; pain scores and adherence
THE PAPER
Daily Pomegranate Intake Has No Impact on PSA Levels in Patients with Advanced Prostate Cancer - Results of a Phase IIb Randomized Controlled Trial.
Stenner-Liewen F, Liewen H, Cathomas R, Renner C, Petrausch U, Sulser T, Spanaus K, Seifert HH, Strebel RT, Knuth A, Samaras P, Müntener M. J Cancer, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.